Abstract

Purpose: Human lung cancer cells were treated using different concentrations of the AGl478 and EGFR signal pathway related inhibitors LY294002, U0126 and AG490. This study aims to explore the role of SOX2 in Non-Small-Cell Lung Cancer (NSCLC).

Methods: Human lung cancer cells were treated by different concentrations of the AGl478 and EGFR signal pathway related inhibitors LY294002, U0126 and AG490. Western blot was used to examine the expression and the nucleus or cytoplasm distribution of SOX2. AKT siRNA and SOX2 siRNA were designed and transfected into H1650 cells. Western blot were employed to determine the transfection efficiencies.

Results: The expression and nuclear translocation level of SOX2 increased by AGl478 were time dependent. LY294002 significantly inhibited the expression of P-SOX2 and induced its nuclear translocation as compared to U0126 and AG490. AKT siRNA depleted the expressions of P-AKT and PSOX2. The expression and nuclear translocation of SOX2 was significantly induced by AGl478 via PI3K/AKT pathway in NSCLC cell lines.

Conclusions: SOX2 can be a potential target of the cancer therapy and drug exploitation in NSCLC.